Morpholino

MO1-pla2g4ab

ID

ZDB-MRPHLNO-160426-2

Name

MO1-pla2g4ab

Previous Names

ATG (1)

Target

pla2g4ab (1)

Sequence

5' - CTCCTTTGGTGACATTTTCAGCCCG - 3'

Disclaimer

Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.

Note

None

Genome Resources

None

Target Location

Genomic Features

No data available

Expression

Gene expression in Wild Types + MO1-pla2g4ab

No data available

Phenotype

Phenotype resulting from MO1-pla2g4ab

Phenotype	Fish	Figures
midbrain decreased size, abnormal	WT + MO1-pla2g4ab	Fig. 4 from Naini et al., 2016

Phenotype of all Fish created by or utilizing MO1-pla2g4ab

Phenotype	Fish	Conditions	Figures
midbrain decreased size, abnormal	WT + MO1-pla2g4ab	standard conditions	Fig. 4 from Naini et al., 2016
head size, ameliorated	WT + MO1-pla2g4ab + MO3-pla2g4aa	chemical treatment: prostaglandin E2	Fig. 4 from Naini et al., 2016
cell cycle G1/S phase transition decreased process quality, abnormal	WT + MO1-pla2g4ab + MO3-pla2g4aa	standard conditions	Fig. 5 from Naini et al., 2016
otolith incomplete structure, abnormal	WT + MO1-pla2g4ab + MO3-pla2g4aa	control	Fig. 4 from Naini et al., 2016
cell cycle G1/S phase transition process quality, ameliorated	WT + MO1-pla2g4ab + MO3-pla2g4aa	chemical treatment: prostaglandin E2	Fig. 5 from Naini et al., 2016
extension decreased length, abnormal	WT + MO1-pla2g4ab + MO3-pla2g4aa	control	Fig. 4 from Naini et al., 2016
whole organism anterior-posterior axis length, ameliorated	WT + MO1-pla2g4ab + MO3-pla2g4aa	chemical treatment: prostaglandin E2	Fig. 4 from Naini et al., 2016
otolith decreased size, abnormal	WT + MO1-pla2g4ab + MO3-pla2g4aa	control	Fig. 4 from Naini et al., 2016
cell cycle G1/S phase transition process quality, ameliorated	WT + MO1-pla2g4ab + MO3-pla2g4aa	chemical treatment: arachidonic acid	Fig. 5 from Naini et al., 2016
cell cycle G1/S phase transition disrupted, abnormal	WT + MO1-pla2g4ab + MO3-pla2g4aa	standard conditions	Fig. 5 from Naini et al., 2016
whole organism anterior-posterior axis length, ameliorated	WT + MO1-pla2g4ab + MO3-pla2g4aa	chemical treatment: arachidonic acid	Fig. 4 from Naini et al., 2016
whole organism anterior-posterior axis decreased length, abnormal	WT + MO1-pla2g4ab + MO3-pla2g4aa	control	Fig. 4 from Naini et al., 2016
head decreased size, abnormal	WT + MO1-pla2g4ab + MO3-pla2g4aa	control	Fig. 4 from Naini et al., 2016
head size, ameliorated	WT + MO1-pla2g4ab + MO3-pla2g4aa	chemical treatment: arachidonic acid	Fig. 4 from Naini et al., 2016

Citations